Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Phosphorus Metabolism Clear all
Completed Phase 1 Interventional

A Study of KRN23 in X-linked Hypophosphatemia

NCT00830674
View directory record Official record
Conditions
X-linked Hypophosphatemia
Interventions
Placebo, KRN23
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
4
States / cities
New Haven, Connecticut • Indianapolis, Indiana • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2024 · Synced Jul 23, 2026, 1:16 AM EDT
Recruiting Phase 2 Interventional

Phosphate in Acute Pancreatitis

NCT07681050
View directory record Official record
Conditions
Pancreatitis
Interventions
Sodium Phosphate, Potassium Phosphate
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 1:16 AM EDT
Suspended Phase 3 Interventional

Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

NCT04523727
View directory record Official record
Conditions
Hyperphosphatemia Related to Chronic Kidney Disease
Interventions
ferric citrate
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
6 Years to 16 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 23, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Results available

Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)

NCT02163577
View directory record Official record
Conditions
X-linked Hypophosphatemia
Interventions
burosumab
Biological
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
5 Years to 12 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced Jul 23, 2026, 1:16 AM EDT
Not listed Phase 2 Interventional

An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients

NCT00834301
View directory record Official record
Conditions
Hyperphosphatemia, Inflammation, Renal Disease
Interventions
Oral Multivitamin
Dietary Supplement
Lead sponsor
Nephrian
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Simi Valley, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2009 · Synced Jul 23, 2026, 1:16 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy

NCT03824587
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Tenapanor, Placebo, Phosphate Binder Agents
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
48
States / cities
Huntsville, Alabama • Pine Bluff, Arkansas • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Jul 23, 2026, 1:16 AM EDT
Completed No phase listed Observational

Studying Phosphorus Metabolism

NCT00066183
View directory record Official record
Conditions
Phosphorus Metabolism
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 1:16 AM EDT
Completed Not applicable Interventional Results available

A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD

NCT00785629
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Calcium acetate, Lanthanum Carbonate, Sevelamer Carbonate, Placebo
Drug
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Jul 23, 2026, 1:16 AM EDT
Completed No phase listed Observational

Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia

NCT00099762
View directory record Official record
Conditions
Osteomalacia, Neoplasms
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
8 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 1:16 AM EDT
Not yet recruiting No phase listed Observational

Treatment Patterns, Biochemical Profiles and Clinical Outcomes in Adults With X-Linked Hypophosphatemia

NCT07607600
View directory record Official record
Conditions
X-linked Hypophosphatemia (XLH)
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
New Haven, Connecticut • Indianapolis, Indiana • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 23, 2026, 1:16 AM EDT
Terminated Phase 3 Interventional

Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate

NCT00841126
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Magnesium iron hydroxycarbonate, Lanthanum carbonate, Placebo
Drug
Lead sponsor
Ineos Healthcare Limited
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2010 · Synced Jul 23, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Results available

Dose Finding Study to Treat High Phosphate Levels in the Blood.

NCT02081534
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
AZD1722, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 85 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
16
States / cities
Downey, California • Los Angeles, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2020 · Synced Jul 23, 2026, 1:16 AM EDT
Completed No phase listed Observational

Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)

NCT00567723
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Not listed
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
2,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
199
States / cities
Birmingham, Alabama • Hoover, Alabama • Mobile, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Jul 23, 2026, 1:16 AM EDT
Completed Phase 2 Interventional

Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis

NCT00704483
View directory record Official record
Conditions
Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy
Interventions
SBR759, Sevelamer HCl
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
19
States / cities
Chula Vista, California • La Mesa, California • Whittier, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jul 23, 2026, 1:16 AM EDT
Completed Phase 3 Interventional Results available

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

NCT03237065
View directory record Official record
Conditions
Iron Deficiency Anaemia, Iron Deficiency Anemia
Interventions
Iron isomaltoside/ferric derisomaltose, Ferric carboxymaltose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Muscle Shoals, Alabama • Doral, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Jul 23, 2026, 1:16 AM EDT
Terminated Phase 1 Interventional

Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)

NCT01748812
View directory record Official record
Conditions
Osteomalacia
Interventions
Osteomalacia
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jul 23, 2026, 1:16 AM EDT
Active, not recruiting No phase listed Observational

X-linked Hypophosphatemia Disease Monitoring Program

NCT03651505
View directory record Official record
Conditions
X-linked Hypophosphatemia, Hypophosphatemic Rickets
Interventions
No intervention
Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 1:16 AM EDT
Completed No phase listed Observational Results available

Long-term Effect of Lanthanum Carbonate on Bone

NCT00557323
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Lanthanum carbonate
Drug
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Lynwood, California • Torrance, California • Springfield, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Jul 23, 2026, 1:16 AM EDT
Completed Phase 4 Interventional

CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients

NCT00211939
View directory record Official record
Conditions
Calcinosis, Arteriosclerosis, Hyperparathyroidism, Secondary
Interventions
calcium acetate, sevelamer, atorvastatin
Drug
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2008 · Synced Jul 23, 2026, 1:16 AM EDT
Completed Phase 4 Interventional

Phosphate Kinetic Modeling 2

NCT01252771
View directory record Official record
Conditions
Hyperphosphatemia, ESRD
Interventions
PKM Algorithm
Other
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Jul 23, 2026, 1:16 AM EDT
Completed Phase 3 Interventional Results available

A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis

NCT01191255
View directory record Official record
Conditions
Hyperphosphatemia, Kidney Failure
Interventions
ferric citrate, ca acetate, sevelamer carbonate, placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
52
States / cities
Tempe, Arizona • Los Angeles, California • Riverside, California + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Jul 23, 2026, 1:16 AM EDT
Completed Phase 4 Interventional Results available

Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients

NCT04046263
View directory record Official record
Conditions
Peritoneal Dialysis Complication, Hyperphosphatemia, Hypoalbuminemia
Interventions
Sucroferric Oxyhydroxide Chewable Tablet
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Jul 23, 2026, 1:16 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

NCT00975000
View directory record Official record
Conditions
Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure, Disordered Mineral Metabolism, End Stage Renal Disease, Hyperparathyroidism, Hypophosphatemia, Kidney Disease, Kidney Transplantation, Post Renal Transplantation
Interventions
Cinacalcet, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
15
States / cities
Phoenix, Arizona • Tempe, Arizona • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Jul 23, 2026, 1:16 AM EDT
Completed Phase 3 Interventional Results available

Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

NCT00772382
View directory record Official record
Conditions
Chronic Kidney Disease, Dialysis, Hyperphosphatemia
Interventions
MCI-196
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
17
States / cities
Los Angeles, California • Orange, California • Tarzana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 23, 2026, 1:16 AM EDT